Identification and Characterization of Breast Tumor Associated Antigens

Abstract

Several aspects of breast cancer research, including detection, diagnostics, staging and immunotherapy strategies would benefit from identification of novel tumor antigens important in breast carcinoma. Because cancer patients exhibit both humoral and cellular immunity to tumor associated proteins, patient sera provides a valuable reagent for the identification of potentially immunogenic tumor associated antigens. We have used serological analysis of recombinant cDNA expression libraries (SEREX) for the identification of tumor antigens in a mouse model of adenocarcinoma and in human breast cancer. cDNA expression libraries derived from cell lines or tumor samples have been screened with autologous and allogeneic sera, and reactive clones have been identified. To date we have identified three candidate tumor antigens which may be important in human breast cancer. The clones encoding putative tumor antigens have been purified and are being characterized with regard to nucleic acid sequence, expression patterns, and reactivity with sera from allogeneic cancer patients. The longterm goal of this work is to develop these novel antigens as potential diagnostic and prognostic markers, and as targets for immunotherapy approaches to breast cancer.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Aug 01, 1998
Accession Number
ADB244279

Entities

People

  • Theresa V. Strong

Organizations

  • University of Alabama

Tags

DTIC Thesaurus Topics

  • Biomedical Research
  • Breast Cancer
  • Cancer
  • Cell Line
  • Cells
  • Chemical Reactions
  • Chemistry
  • Cultured Cells
  • Gene Expression
  • Gene Therapy
  • Genetic Structures
  • Genetics
  • Identification
  • Immune Serums
  • Immunity
  • Molecules
  • Proteins

Fields of Study

  • Biology
  • Medicine

Readers

  • Immunology
  • Molecular Genetics
  • Molecular and genetic basis of cancer.

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech